MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine

Jan 24, 2025 | Press Releases

HDT Bio’s LION™ platform to support malaria vaccine development by MalarVx SEATTLE, Jan. 15, 2025 /PRNewswire/ — MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio’s proprietary self-amplifying replicon RNA...

Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68

Nov 13, 2024 | In the News

Click here to view...

Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines

Sep 19, 2024 | In the News

Click here to view...

HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative

Sep 17, 2024 | Press Releases, Uncategorized

HDT bio’s Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ — HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies,...

HDT Bio Publishes Peer-Reviewed Article Describing the Development of an RNA Vaccine to Prevent Infection and Disease Caused by Enterovirus D68

Aug 7, 2024 | Press Releases

Self-amplifying RNA vaccine, delivered by cationic nanocarrier (LION™) elicits neutralizing antibody responses in mice and nonhuman primates and protects mice from enterovirus D68 (EV-D68) respiratory infection and resulting disease in mice. Findings published in the...